Groningen, The Netherlands, 9 May 2016 - Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that the first four patients have been enrolled in the “STOP NEUROMA” study.
The STOP NEUROMA study (Surgical Treatment Of symPtomatic Neuroma) will examine the effectiveness of the company’s device NEUROCAP® in the reduction of painful neuroma formation. NEUROCAP® is a transparent tubular device with a sealed end, and is the first and only synthetic nerve capping device cleared for the treatment of symptomatic neuromas. The patients have been enrolled at the MCGroep hospital in Emmeloord, The Netherlands, by Coordinating Investigator, Marietta Bertleff, MD.
Dr Bertleff said, “Neuropathic pain caused by symptomatic neuromas is an important problem following peripheral nerve injury. The treatment of such disabling neuropathic pain following nerve injury is a topic that is of timeless interest to surgeons but an entirely effective treatment remains elusive. The STOP NEUROMA study is designed to support surgeons with clinical evidence about NEUROCAP® for the much needed management of symptomatic neuroma pain to improve patients’ daily life and functioning.”
Rudy Mareel, CEO a.i. of Polyganics said, “Our active recruitment to the STOP NEUROMA study, which uses our nerve stump barrier NEUROCAP®, is another significant milestone for Polyganics. This work helps us to gain traction in an important market: in the US alone there are approximately 600,000 nerve repair procedures per year. We strongly believe NEUROCAP® represents an important addition to our peripheral nerve repair portfolio of products designed to enhance patient recovery and surgical outcomes.”
The STOP NEUROMA study (Surgical Treatment Of symPtomatic Neuroma) will examine the effectiveness of the company’s device NEUROCAP® in the reduction of painful neuroma formation. NEUROCAP® is a transparent tubular device with a sealed end, and is the first and only synthetic nerve capping device cleared for the treatment of symptomatic neuromas. The patients have been enrolled at the MCGroep hospital in Emmeloord, The Netherlands, by Coordinating Investigator, Marietta Bertleff, MD.
Dr Bertleff said, “Neuropathic pain caused by symptomatic neuromas is an important problem following peripheral nerve injury. The treatment of such disabling neuropathic pain following nerve injury is a topic that is of timeless interest to surgeons but an entirely effective treatment remains elusive. The STOP NEUROMA study is designed to support surgeons with clinical evidence about NEUROCAP® for the much needed management of symptomatic neuroma pain to improve patients’ daily life and functioning.”
Rudy Mareel, CEO a.i. of Polyganics said, “Our active recruitment to the STOP NEUROMA study, which uses our nerve stump barrier NEUROCAP®, is another significant milestone for Polyganics. This work helps us to gain traction in an important market: in the US alone there are approximately 600,000 nerve repair procedures per year. We strongly believe NEUROCAP® represents an important addition to our peripheral nerve repair portfolio of products designed to enhance patient recovery and surgical outcomes.”
